ADDITION OF HOUSTON-BASED LAB WILL INCLUDE PROPRIETARY APOSTREAM®
LIQUID BIOPSY TECHNOLOGY, FURTHER EXPANDING PRECISION’S LARGE ARRAY
OF BIOMARKER CAPABILITIES
Bethesda, MD – October 16, 2018
Precision for Medicine, part of the Precision Medicine Group, announced today it has acquired
Houston-based ApoCell, a next-generation lab specializing in the identification and analysis of biomarkers.
The acquisition adds the ApoStream® liquid biopsy technology and deep expertise in tissue profiling to
Precision’s robust suite of specialty laboratory and biomarker informatics services. Providing these advanced
capabilities to clients further positions Precision as a scientific frontrunner in the rapidly expanding
precision medicine space.
ApoCell co-developed the ApoStream liquid biopsy technology in conjunction with the National Cancer
Institute (NCI). ApoStream is a breakthrough, liquid biopsy technology to detect, isolate, and capture
circulating tumor cells (CTCs) and other rare cells without the need of labels or antibodies. Liquid
biopsies use whole blood to assess biomarkers typically only accessible through invasive tumor biopsies,
offering patients less invasive, less painful, and more economical diagnostic options.
The ApoStream technology has been incorporated into over 75 clinical studies, including trials for
prostate, lung, breast, colon, pancreatic, liver, sarcoma, and renal cancers. In addition, ApoCell has been
a pioneer in developing the technology for high-volume capture of CTCs to enable precision medicine in
the clinical setting.
As a pioneer in tissue profiling, ApoCell offers a unique integrated platform, built to work with tumor
tissue to generate both phenotypic and genomic information from the same biopsy sample. ApoCell
specializes in high complexity, multiplex immunofluorescence detection using a state-of-the-art image
analysis to address complex questions regarding frequency of cell populations for immuno-oncology
“We are very excited to welcome the ApoCell team of highly trained scientists, clinicians, and
technological experts to Precision,” said Precision for Medicine President Chad Clark. “The acquisition of
ApoCell complements the portfolio of specialty services that Precision offers to its clients in an
important way—by adding advanced laboratory and tissue profiling capabilities, along with the
ApoStream liquid biopsy technology to our comprehensive set of translational sciences solutions.”
“Precision for Medicine is a perfect partnership for us,” said ApoCell CEO Dr. Darren Davis. “By joining
with Precision, we can now offer our existing clients a full suite of data management and biomarker
analytics capabilities, and also leverage Precision’s global reach and robust clinical trial services. We
remain committed to continuing innovation that delivers on the promise of personalized medicine and
improving the lives of patients with debilitating diseases.”
With the addition of ApoCell, Precision continues to build the infrastructure, technology, and specialized
scientific personnel required for new approaches to precision medicine drug development on a global
scale, remaining at the forefront of the worldwide shift to precision medicine.
About Precision for Medicine
Precision for Medicine supports life sciences companies in the use of biomarkers essential to targeting
patients more precisely and effectively. Precision applies novel biomarker approaches to clinical
research that take advantage of the latest advancements in science and technology, focusing
predominantly on genomics, immune-response assays, global specimen logistics, biomarker analytics,
companion diagnostics, and clinical trial execution. Precision for Medicine is part of Precision Medicine
Group, with more than 1,450 employees in 30 locations in the US, Canada, and Europe. For more
information, visit precisionformedicine.com.
ApoCell focuses its efforts on the identification and analysis of biomarkers in rare circulating cells.
Utilizing innovative liquid biopsy biomarker technologies including the ApoStream® technology tool,
ApoCell facilitates a deeper understanding of the pharmacodynamics of a drug candidate, enabling
go/no go decisions to be made earlier than ever before. More information can be found at
http://www.ApoCell.com and http://www.apostream.com.
Louis Landon, Precision Medicine Group Media Relations